Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.48 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.44 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.44 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29840672 | 1.00 | CTSL (0.50) | CTSLS1PR3KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL16690741 | 1.00 | CTSL (0.50) | CTSLS1PR3KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL4597970 | 1.00 | CTSL (0.50) | CTSLS1PR3KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL4597836 | 0.90 | CTSL (0.48) | CTSLS1PR3CTSSCTSKMAPK1 | |
| SCHEMBL4597438 | 0.90 | CTSL (0.48) | CTSLS1PR3CTSSCTSKMAPK1 | |
| SCHEMBL27955102 | 0.90 | CTSL (0.48) | CTSLS1PR3CTSSCTSKPHGDH | |
| SCHEMBL17691230 | 0.90 | CTSL (0.48) | CTSLS1PR3KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL19731347 | 0.90 | CTSL (0.48) | CTSLS1PR3CTSSCTSKMAPK1 | |
| SCHEMBL742764 | 0.88 | CTSL (0.50) | CTSLS1PR3CTSSCTSKDCAF1 | |
| SCHEMBL20879151 | 0.88 | CTSL (0.47) | CTSLS1PR3CTSSCTSKKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113200961-B | Heterocyclic inhibitors of ERK1 and ERK2 and their use in cancer treatment | 阿沙纳生物科学公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-114901274-A | Improved methods, kits, compositions and dosing regimens using heterocyclic inhibitors of ERK1 and ERK2 | 阿沙纳生物科学公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-113200961-A | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | 阿沙纳生物科学公司 | 2021-08-03 | — | — | CN | disclosed |
| CN-105658646-B | Aminoheteroaryl benzamide as kinase inhibitor | 诺华股份有限公司 | 2018-11-27 | — | — | CN | disclosed |
| EP-2408751-B1 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER IP GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| CN-105658646-A | Aminoheteroaryl benzamides as kinase inhibitors | 诺华股份有限公司 | 2016-06-08 | — | — | CN | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | CTSL 1387/4885S1PR3 68/4885KCNQ3 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.